SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as the community discusses its potential role in real-world asset tokenization and its eco-friendly proof-of-stake mechanism. Bullish community members point to Algorand's technological advantages and strategic partnerships, while others debate its marketing and current leadership, with some suggesting the need for a change in direction to capture more market share in the crypto space. Community members also debate price predictions and technical analysis.

Bridging Real World Asset (RWA) With Blockchain. Own, Invest and Earn Through NFTs on #Solana.

Sky Hause

Sky Hause ($SKYH.X) is trending as community members express bullish sentiment and anticipate significant gains. Conversations suggest a potential breakout and compare the coin's trajectory to other popular cryptocurrencies. However, some users are also expressing concerns.

Pump.fun

$PUMP.X is trending as community members actively discuss its potential as the next big mover in the meme coin space, drawing comparisons to $DOGE.X. Bullish sentiment is fueled by the token's presence on the X news page and the belief that it's still early to invest. Some users highlight the project's ecosystem and community-driven initiatives as key factors for its potential growth within the Solana network.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending as the community rallies behind its potential, drawing comparisons to $MYX.X and highlighting its backers. Bullish sentiment is fueled by its position as a top gainer on Coinbase and speculation around upcoming catalysts like RWA asset trading. Traders are watching for a potential run to $1 and beyond, citing its leveraged trading on-chain.

Trump For President

$TRUMP.X is trending as community members discuss its potential for significant gains, citing key resistance breaks and anticipating a major pump. Some users are pointing to potential factors such as news or market dynamics, while others express skepticism, referencing past performance. Overall, the coin's volatility and association with a prominent political figure are driving heightened interest and speculative conversation.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates the launch of the first U.S. Dogecoin ETF (DOJE) next week, with many expressing excitement and setting price targets. Bullish sentiment is fueled by broader discussions around altcoin season and potential impacts from BlackRock's Bitcoin ETF plans. Community members are actively debating entry points, holding strategies, and potential price movements, while also watching for cues from prominent figures like Elon Musk.

Blunny revives the lost feeling of being a CHAD in crypto projects. Join us on BASE CHAIN to build a safe community of like-minded chads.

Blunny

Blunny ($BLUNNY.X) is trending as social media buzz suggests potential upward movement. Community members are using phrases like "about to pop" and "blow," indicating excitement around possible near-term gains. The coin is also receiving shout-outs from other crypto communities, such as Jasmy ($JASMY.X) and Bunker ($BNKR.X).

TOSHI

TOSHI.X is gaining traction, with community members anticipating a breakout and discussing potential catalysts like a Binance listing and the upcoming FED meeting. Bullish sentiment is fueled by comparisons to other meme coins and the growing Reddit community, as well as analysis of the chart. Some investors suggest accumulating on dips in anticipation of a significant move.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as traders assess potential impacts from executive actions and tariff discussions. The community is actively debating whether current events present a buying opportunity or signal further declines, with some noting technical indicators suggesting a possible bounce. Broader market sentiment and sector rotation are also factors influencing LABU's price action.

Spell Token

Spell Token is trending as the community discusses potential catalysts and partnerships, while some express frustration with its inability to hold gains. Despite some negative sentiment regarding dilution, there's anticipation for a potential surge, with some eyeing a "penny" target.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings

While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pacira (PCRX) Tops Q2 Earnings Estimates

Pacira (PCRX) delivered earnings and revenue surprises of +2.78% and -1.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Pacira BioSciences Inc (PCRX) traded 19% higher on Tuesday morning, following upward price target revisions by multiple brokerages following a patent litigation settlement.Pacira <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.pacira.com/news-releases/news-release-details/pacira-biosciences-announces-settlement-us-patent-litigation">announced</a> on Monday that it has settled its litigations related to patents for EXPAREL or bupivacaine liposome injectable suspension, a long-acting local pain reliever.As part of the settlement, Pacira agreed to provide Fresenius Kabi USA, LLC with a license to Pacira’s patents required to manufacture and sell certain volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. beginning on a confidential date sometime in early 2030.Pacira also agreed to provide Fresenius with a license to Pacira’s patents required to manufacture and sell an unlimited quantity of generic bupivacaine liposome injectable suspension in the U.S. beginning no earlier than 2039.Pacira CEO Frank D. Lee said Monday that the settlement agreement provides “clarity” around EXPAREL exclusivity.Meanwhile, H.C. Wainwright raised the firm's price target on Pacira to $65 from $48 while keeping a ‘Buy’ rating on the shares.The firm opined that the Street is "wildly overestimating" the company's Exparel generic risk and "dramatically underpricing" Pacira shares, according to TheFly.RBC Capital also raised its price target on Pacira to $26 from $22 on Tuesday and maintained a “Sector Perform” rating on the shares.Pacira BioSciences’ settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and the Exparel franchise, the analyst said.It brings needed clarity and five years of protection to potentially realize the benefits of internal drivers, the analyst told investors in a research note.Truist also raised its price target on Pacira to $28 from $25 and kept a ‘Hold’ rating on the shares. The firm now envisions peak Exparel sales of $740 million by 2029.On Stocktwits, retail sentiment about PCRX jumped from ‘extremely bearish’ to ‘extremely bullish’ territory while message volume jumped from ‘high’ to ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:650/150;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_08_at_10_20_15_AM_png_84a9d54519.webp" alt="PCRX's Sentiment Meter and Message Volume as of 10:20 a.m. ET on April 8, 2025 | Source: Stocktwits" width="650" height="150"><figcaption>PCRX's Sentiment Meter and Message Volume as of 10:20 a.m. ET on April 8, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/PCRX">PCRX Shares</a> have risen nearly 49% this year but have fallen over 4% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cvs-health-appoints-new-cfo-chief-medical-officer/chflzodRbJf">CVS Health Appoints New CFO, Chief Medical Officer: Retail Sentiment Soars</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Pacira Biosciences Stock Rises On Multiple Price Target Upgrades: Retail Sentiment Soars

RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and the Exparel franchise.

Equity

Shares of Pacira BioSciences Inc. soared over 22% in extended trading on Monday after the company said it had resolved a legal case over its long-acting pain medication.&nbsp;Pacira has settled litigation with Germany's Fresenius Kabi and its partners over patents related to Exparel, which reportedly provides&nbsp;pain&nbsp;relief for up to 72 hours after surgery.As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030, when it will be allowed limited entry into the U.S. market under a confidential volume cap.The licensed volumes will start in the high single-digit percentage range and gradually increase each year, reaching the high thirty percent by the agreement's final years.&nbsp;Still, Fresenius will be permitted to sell unlimited volumes of its generic version starting in 2039, before Pacira's last-listed Exparel patent expires in July 2044.&nbsp;On Stocktwits, sentiment for Pacira jumped into ‘extremely bullish’ levels late Monday, accompanied by a 50% jump in message volume over the last 24 hours.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/PCRX_sentiment_and_message_volume_as_of_April_7_png_47dd0566cd.webp" alt="PCRX sentiment and message volume as of April 7.png" width="1318" height="316"><figcaption>PCRX sentiment and message volume as of April 7. | source: Stocktwits</figcaption></figure>"The settlement terms are notably favorable for Pacira. They've secured full exclusivity until early 2030 - providing at least 5 more years of uncontested market presence," said one user.<stembedurl>https://stocktwits.com/GoldKing23/message/610799845</stembedurl>"Market hates uncertainty—this clears the deck," posted another.<stembedurl>https://stocktwits.com/Rage_Against_The_Machine/message/610799401</stembedurl>In December 2024, Pacira was granted a U.S. Patent covering the chemical composition of Exparel.That same month, the company filed a lawsuit in Illinois to defend Exparel against generic challengers.<a href="https://stocktwits.com/symbol/PCRX">Pacira’s stock</a> has gained more than 20% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pacira Biosciences Stock Surges After-Hours On Exparel Patent Settlement: Retail Investors Rejoice

As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030.

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud...

Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline

Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of...

Pacira BioSciences, Inc. Class Action: The Gross Law Firm Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX

Pacira BioSciences, Inc. Class Action: The Gross Law Firm Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX Pacira BioSciences, Inc...

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit PR Newswire NEW...

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX PACIRA...

Investors who lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky about pending Class Action - PCRX

Investors who lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky about pending Class Action - PCRX Investors who lost money on Pacira BioSciences, Inc.(PCRX) should contact...

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.65	--	--	N/A
Q2 '25	$0.71	$0.74	4.23%	BEAT
Q1 '25	$0.60	$0.62	3.94%	BEAT
Q4 '24	$0.84	$0.91	8.94%	BEAT
Q3 '24	$0.70	$0.79	12.14%	BEAT

PCRX
Pacira BioSciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest PCRX News

PCRX Pacira BioSciences Inc